

Org nr 556966-4955
October 2, 2026



Elicera Therapeutics to participate in upcoming investor and partnering events

Uppsala, Sweden, October 2 2026 – Elicera Therapeutics AB (publ) today announces that the company will participate in several industry, partnering and investor conferences in Sweden, Europe and the US during the fourth quarter of 2026. At these events, the company will present its business, the latest results from the Phase I part of the CARMA clinical study of the CAR T-cell therapy ELC-301, and its proprietary iTANK platform.

Elicera develops next-generation immuno-oncology treatments based on iTANK-armed CAR T cells and oncolytic viruses. The company's CAR T-cell therapy ELC-301 is being evaluated in the Phase I/IIa clinical study CARMA for the treatment of patients with B-cell lymphoma who have no remaining treatment options. The Phase IIa part of the study has been approved by the Swedish Medical Products Agency, and patient recruitment is expected to begin in the fourth quarter of 2026.

During the fourth quarter of 2026, Elicera Therapeutics will participate in the following meetings and conferences:

Cell & Gene Meeting on the Mesa 2026

October 5-7, Phoenix, USA

Partnering meeting for the cell and gene therapy sector, organised by the Alliance for Regenerative Medicine (ARM). <https://meetingonthemesa.com>

Symposium on the Future of Cell and Gene Therapy, hosted by CCRM

October 22, Gothenburg, Sweden

Elicera's CEO Johan Liwing has been invited to take part in a panel discussion entitled "Bridging the competitiveness gap for ATMPs".

BioStock Life Science Summit 2026

November 4-5, Lund, Sweden

CEO Johan Liwing will present the company on 4 November at 13:45 CET.

<https://biostock.se/en/event/life-science-summit-2026/>

Advanced Therapies USA 2026

November 4-5, Boston, USA

Congress and partnering meeting focused on the development and manufacturing of cell and gene therapies. Chair of the Board Margareth Jorvid will give a presentation on the topic "Effectively interacting with regulatory authorities" and take part in a panel discussion entitled "Navigating the Global Regulatory Landscape".

<https://www.terrapinn.com/conference/advanced-therapies-usa/>

BIO-Europe 2026

November 9-11, Cologne, Germany

Europe's largest partnering conference for the pharmaceutical and biotech industries.

<https://informaconnect.com/bioeurope/>

ATMP Sweden 2026 Conference

December 1-2, Campus Flemingsberg, Stockholm

Nordic conference on advanced therapy medicinal products (ATMPs), bringing together industry, academia and healthcare. <https://atmpsweden.se/event/atmp-sweden-2026-conference/>

Redeye Life Science Day 2026

December 2, Stockholm

CEO Johan Liwing will present the company in the morning. The presentation will be broadcast live on www.redeye.se and will be available on demand afterwards.

<https://www.redeye.se/events>

Pharma Outsourcing 2026

December 2, Stockholm

CEO Johan Liwing has been invited to give a presentation entitled "Building for the Next Clinical Stage – How a Cell & Gene Therapy Biotech Needs to Evolve".

<https://nmevents.se/pharmaoutsourcing>

"Backed by the positive results reported from the Phase I part of the CARMA study, we are entering a period with many opportunities to meet potential partners, investors and other players in the cell and gene therapy field. We look forward to presenting Elicera, ELC-301 and the iTANK platform, and to deepening our dialogue with both industry and the capital markets, in Sweden as well as internationally," says Johan Liwing, CEO of Elicera Therapeutics.

For further information please contact:

Johan Liwing, CEO, Elicera Therapeutics AB

Phone: +46 (0) 706 70 36 75

johan.liwing@elicera.com

Certified Advisor

DNB Carnegie Investment Bank (publ)

About the CARMA Study

CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third cohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge.

About ELC-301

ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company's iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells.

About the iTANK-platform

The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells

expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: <https://www.nature.com/articles/s41551-022-00875-5>. More information about iTANK platform is available here: <https://www.elicera.com/technology>

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.